Cellular accumulation of aggregated forms of the protein tau is a defining feature of so-
called tauopathies such as Alzheimer's disease, progressive supranuclear palsy, and …

Since diagnosis of Parkinson's disease (PD) is mostly based on clinical criteria, it is almost
impossible to formulate an early diagnosis, as well as a timely differential diagnosis versus …

Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …

Tau is an axonal microtubule-binding protein. Tau pathology in brain and increased tau
concentration in the cerebrospinal fluid (CSF) are hallmarks of Alzheimer's disease (AD) …

Background and Objectives Phosphorylated tau (p-tau) in CSF is considered an important
biomarker in Alzheimer disease (AD) and has been incorporated in recent diagnostic …

To date, there is no validated fluid biomarker for tau pathology in Alzheimer's disease, with
contradictory results from studies evaluating the correlation between phosphorylated tau in …

Background Recent advances in disease-modifying treatments highlight the need for
accurately identifying individuals in early Alzheimer's disease (AD) stages and for …

Given the growing use of cerebrospinal fluid (CSF) beta-amyloid (Aβ) and tau as biomarkers
for early diagnosis of Alzheimer's disease (AD), it is essential that the diagnostic procedures …

Background and Objectives Injured pericytes in the neurovascular unit release platelet-
derived growth factor β (PDGFRβ) into the CSF. However, it is not clear how pericyte injury …

Purpose Studies comparing CSF and PET tau biomarkers have included only commercial
CSF assays examining specific phosphorylation sites (eg threonine 181, P-tau 181p) and …